Orchard Therapeutics PLC
Matthew Turley is a Senior Scientist with extensive experience in conducting research related to cardiomyocytes derived from human induced pluripotent stem cells (iPSCs) and cardioprotective signalling pathways. Matthew has a background in molecular biology and has utilized various techniques such as RTqPCR, Western blot, and CRISPR/Cas9 gene editing in their work. Matthew has also been involved in organizing departmental seminar series and serving as a Postdoc Representative. Matthew holds a PhD in Molecular Biology from The University of Freiburg and a Bachelor's Degree in Molecular Cell Biology from The University of York.
Orchard Therapeutics PLC
3 followers
Orchard Therapeutics plc, formerly Orchard Rx Ltd, is a commercial-stage, fully-integrated biopharmaceutical company. It is engaged in manufacturing and commercialization of gene and cell therapies, position to provide transformative therapies to patients suffering from a range of rare diseases. The Company is focused on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders and hemoglobinopathies. Its portfolio includes Strimvelis, its commercial-stage gammaretroviral-based product for the treatment of ADA-SCID five lentiviral product candidates in clinical-stage development and several other product candidates in preclinical development. It is developing OTL-101 as an autologous ex vivo lentiviral gene therapy to sustainably treat patients with adenosine deaminase severe combined immunodeficiency (ADA-SCID) through a single administration.